1-30) and its analogues: stability and mechanisms of insulinotropic action. The Journal of endocrinology, 232, 423-435. https://doi.Abstract 21 The insulin-releasing effects, cellular mechanisms of action and anti-hyperglycaemic activity 22 of 10 analogues of esculentin-2CHa lacking the cyclic C-terminal domain (CKISKQC) were 23 evaluated. Analogues of the truncated peptide, esculentin-2CHa(1-30), were designed for 24 plasma enzyme resistance and increased biological activity. Effects on insulin release, cell 25 membrane integrity, membrane potential, intracellular Ca 2+ and cAMP levels were 26 determined using clonal BRIN-BD11 cells. Acute effects on glucose tolerance were 27 investigated using NIH Swiss mice. D-amino acid substitutions at positions 7(Arg), 15(Lys) 28 and 23(Lys) and fatty acid (L-octanoate) attachment to Lys at position 15 of esculentin-29 2CHa(1-30) conveyed resistance to plasma enzyme degradation whilst preserving insulin-30 releasing activity. Analogues [D-Arg 7 , D-Lys 15 , D-Lys 23 ]-esculentin-2CHa(1-30) and Lys 15 -31 octanoate-esculentin-2CHa(1-30) exhibiting most promising profiles and with confirmed 32 effects on both human insulin-secreting cells and primary mouse islets were selected for 33 further analysis. Using chemical inhibition of adenylate cyclase, protein kinase C or 34 phospholipase C pathways, involvement of PLC/PKC mediated insulin secretion was 35 confirmed similar to that of CCK-8. Diazoxide, verapamil and Ca 2+ omission inhibited 36 insulin secretion induced by the esculentin-2CHa(1-30) analogues suggesting an action also 37 on K ATP and Ca 2+ channels. Consistent with this, the analogues depolarised the plasma 38 membrane and increased intracellular Ca 2+ . Evaluation with fluorescently labelled esculentin-39 2CHa(1-30) indicated membrane action, with internalisation, but patch clamp experiments 40
Introduction
Incidence of type 2 diabetes is constantly on the rise, owing to an increase in consumption of a western diet, sedentary lifestyle, obesity and aging population (Stumvoll et al. 2008, 30) and selected analogues were examined over a similar concentration range using 1.1B4 145 human clonal beta cells (McCluskey et al. 2011 , Green et al. 2015 . In a third set of 146 experiments, pancreatic islets isolated from NIH Swiss mice by collagenase digestion (Gotoh 147 et al. 1985) , were incubated with 10 -6 and 10 -8 M of esculentin-2CHa(1-30) and selected 148 analogues for 1 h in Krebs-Ringer bicarbonate (KRB) buffer supplemented with 3 or 20 mM 149 glucose. Other experiments detailed below were conducted at peptide concentration of 10 -6 M 150 which elicited prominent insulin secretory effects. Insulin release was measured by 151 radioimmunoassay (Flatt & Bailey, 1981a , Flatt & Bailey, 1981b using mouse or human 152 insulin standards as appropriate.
153

Membrane potential studies and intracellular calcium ([Ca 2+ ] i ):
Effects of esculentin-154 2CHa(1-30) and analogues on membrane potential and intracellular calcium [Ca 2+ ] i were 155 assessed using BRIN-BD11 cells (FLIPR membrane or calcium assay kit, Molecular 156 Devices, USA) as previously described (Miguel et al. 2004) . BRIN-BD11 cells were pancreatic β-cells using the whole-cell mode of the patch clamp technique as previously 170 described (Ojo et al. 2016) . Amphotericin B was included in the pipette solutions to perforate 171 the membrane and reduce current run-down such that currents were stable for the duration of 172 the recording (Ojo et al. 2016) . Current densities were calculated by dividing current 173 amplitudes by the whole-cell capacitance (6-19 pF) . External drug containing solutions were 174 applied using a gravity-driven perfusion system with an exchange time of approximately 1s 175 (Scholfield & Curtis, 2000) . K ATP currents were elicited by ramp protocols from +20 to -80 176 mV applied over 1 second from a holding potential of 0 mV using high K + external solution 177 (containing in mM: 130 KCl, 10 TEACl, 2.5 Glucose, 1.3 MgCl 2 , 2 CaCl 2 , 10 HEPES pH 7.4 178 with NaOH). 100nM penitrem A, 1mM 4,4′-diisothiocyanatostilbene-2,2′-disulfonate (DIDS) 179 and 1μM nimodipine were added to inhibit BK, Cland L-Type Ca 2+ channels and a K + - (NIH publication no. 86 -23, revised 1985) . 
Results
205
Plasma stability of esculentin-2CHa(1-30) and analogues: 206 Degradation of esculentin-2CHa(1-30) (Peptide 1) exposed to mouse plasma was 93% in 8 207 hours ( Table 2) . Examination of degradation products by mass spectrometry suggests that the 208 native peptide is cleaved by enzymes at the following sites: between Phe 6 and Arg 7 , Arg 7 and 209 Gly 8 , Lys 11 and Phe 12 , Ser 14 and Lys 15 , Leu 17 and Gly 18 , Ala 22 and Lys 23 and Leu 28 and Val 29 .
210
Substitution with D-isomers of residues at position 7 (Peptide 2), position 15 (Peptide 3) and 211 positions 7, 15 and 23 (Peptide 6) conferred resistance to degradation, with degradation 212 ranging between 24-59% (Table 2) . Substitution with D-lysine residues at position 23 213 (Peptide 4) and at positions 15 and 23 (Peptide 5) reduced degradation to approximately 80% 214 (Table 2) . Peptide 6 was cleaved only at Lys 11 and Phe 12 and Leu 28 and Val 29 compared to 215 esculentin-2Cha-GA30, thus substitution of residues with D-isomers at these positions 216 protected the sites from enzymatic cleavage. Substitution of lysine residues at positions 15 217 and 23 with L-ornithine (Peptide 7) and amidation of C-terminus (Peptide 8) did not confer 218 resistance to degradation ( Table 2) . Addition of a C-8 fatty acid to lysine residue at position 15 (Peptide 9) or 23 (Peptide 10) conferred resistance to degradation (62 and 79% 220 respectively, Table 2) , with cleavage only at sites between Arg 7 and Gly 8 , Ala 22 and Lys 23 and 221 Leu 24 and Gly 25 and Arg 7 and Gly 8 and Leu 24 and Gly 25 respectively.
222
Insulinotropic actions of esculentin-2CHa(1-30) and analogues: 223 Esculentin-2CHa(1-30) (Peptide 1) and analogues stimulated insulin release from BRIN-224 BD11 cells significantly compared to respective control at glucose (5.6 mM) (p<0.05, 225 p<0.01, p<0.001, Table 2 ). Substitution of residues at position 7 (Peptide 2), position 15 Table 2 ). Amidation of C-terminus (Peptide 8) did not markedly affect insulin output from 232 BRIN-BD11 cells compared to parent peptide ( Table 2) . Addition of a C-8 fatty acid to lysine 233 residue at position 15 (Peptide 9) or 23 (Peptide 10) markedly increased insulin release from 234 BRIN-BD11 cells (p<0.001, Table 2), with effects of Peptide 9 significantly greater than BRIN -BD11 cells (p<0.05, p<0.01, p<0.001, Figure 2B Figure 3B ). : Esculentin-2CHa (1-30) and its 290 analogues (Peptide 6 and 9) increased membrane potential and depolarised BRIN-BD11 cells 291 compared to 5.6 mM glucose control (p<0.05, p<0.01, p<0.001, Figure 4A,B) . This was accompanied by a significant increase in intracellular [Ca 2+ ] i (p<0.05, p<0.001, Figure 4C,D) .
289
Effects on membrane potential and intracellular Ca 2+
293
The magnitude of the effects was markedly less than that induced by a depolarising 294 concentration of KCl but similar to GLP-1 (Figure 4) .
295
Actions at plasma membrane: 296 FITC-esculentin-2CHa(1-30) was used to monitor interactions of the peptide at plasma Figure 4A was unlikely to be due to direct action of the peptide on K ATP channels 307 as when membrane current was recorded under selective recording conditions using the patch 308 clamp technique, Peptide 6 (1 μM) had no effect on the amplitude of diazoxide activated acid sequences and molecular masses of esculentin-2CHa, esculentin-2CHa(1-30) Glucose (16.7 mM) --1.36 ± 0.10 *** --106.9 ± 1.3
Alanine (10 mM) --5.00 ± 0.50 *** --106.1 ± 1.8
GLP-1 (7-36) NH 2 (10 -6 M) ----10 -6 10 -7 10 -8 10 -9 10 -10 10 -11 10 -12 10 -6 10 -7 10 -8 10 -9 10 -10 10 -11 10 -12 10 -6 10 -7 10 -8 10 -9 10 -10 10 - 
